Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Corixa, Zambon collaborate to develop lung cancer immunotherapeutic vaccines

May 25, 1999

K1-5 is a more potent angiogenesis inhibitor than angiostatin

May 25, 1999

MMP inhibitor MMI-270 tested in cancer patients in combination with 5-FU/folinic acid

May 24, 1999

Compounds in development at Shionogi reverse oncogene-induced cell transformation

May 24, 1999

Positive findings from phase I trial of LY-353381 reported at ASCO meeting, lead to phase II study

May 21, 1999

PDT with temoporfin is a promising treatment for GI tumors

May 21, 1999

CCK-B/gastrin antagonist CR-2945 prevents colorectal cancer in mice

May 21, 1999

First proteasome inhibitor in clinical development profiled at oncology meeting

May 20, 1999

Favorable pharmacokinetic, safety and efficacy profile for FMdC in phase I; phase II trials begin

May 20, 1999

Leinamycin derivative selected by Kyowa Hakko for further development

May 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...